Literature DB >> 10445007

Methylation of inorganic arsenic in different mammalian species and population groups.

M Vahter.   

Abstract

Thousands of people in different parts of the world are exposed to arsenic via drinking water or contaminated soil or food. The high general toxic of arsenic has been known for centuries, and research during the last decades has shown that arsenic is a potent human carcinogen. However, most experimental cancer studies have failed to demonstrate carcinogenicity in experimental animals, indicating marked variation in sensitivity towards arsenic toxicity between species. It has also been suggested that there is a variation in susceptibility among human individuals. One reason for such variability in toxic response may be variation in metabolism. Inorganic arsenic is methylated in humans as well as animals and micro-organisms, but there are considerable differences between species and individuals. In many, but not all, mammalian species, inorganic arsenic is methylated to methylarsonic acid (MMA) and dimethylarsinic acid (DMA), which are more rapidly excreted in urine than is the inorganic arsenic, especially the trivalent form (AsIII, arsenite) which is highly reactive with tissue components. Absorbed arsenate (AsV) is reduced to trivalent arsenic (AsIII) before the methyl groups are attached. It has been estimated that as much as 50-70% of absorbed AsV is rapidly reduced to AsIII, a reaction which seems to be common for most species. In most experimental animal species, DMA is the main metabolite excreted in urine. Compared to human subjects, very little MMA is produced. However, the rate of methylation varies considerably between species, and several species, e.g. the marmoset monkey and the chimpanzee have been shown not to methylate inorganic arsenic at all. In addition, the marmoset monkey accumulates arsenic in the liver. The rat, on the other hand, has an efficient methylation of arsenic but the formed DMA is to a large extent accumulated in the red blood cells. As a result, the rat shows a low rate of excretion of arsenic. In both human subjects and rodents exposed to DMA, about 5% of the dose is excreted in the urine as trimethylarsine oxide. It is obvious from studies on human volunteers exposed to specified doses of inorganic arsenic that the rate of excretion increases with the methylation efficiency, and there are large inter-individual variations in the methylation of arsenic. Recent studies on people exposed to arsenic via drinking water in northern Argentina have shown unusually low urinary excretion of MMA. Furthermore, children had a lower degree of methylation of arsenic than adults. Some studies indicate a lower degree of arsenic methylation in men than in women, especially during pregnancy. Whether the observed differences in methylation of arsenic are associated with variations in the susceptibility of arsenic remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445007     DOI: 10.1177/003685049908200104

Source DB:  PubMed          Journal:  Sci Prog        ISSN: 0036-8504            Impact factor:   2.774


  82 in total

Review 1.  State of the science review of the health effects of inorganic arsenic: Perspectives for future research.

Authors:  Paul B Tchounwou; Clement G Yedjou; Udensi K Udensi; Maricica Pacurari; Jacqueline J Stevens; Anita K Patlolla; Felicite Noubissi; Sanjay Kumar
Journal:  Environ Toxicol       Date:  2018-12-04       Impact factor: 4.119

Review 2.  Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals.

Authors:  David J Thomas; Jiaxin Li; Stephen B Waters; Weibing Xing; Blakely M Adair; Zuzana Drobna; Vicenta Devesa; Miroslav Styblo
Journal:  Exp Biol Med (Maywood)       Date:  2007-01

3.  Effects of prenatal exposure to sodium arsenite on motor and food-motivated behaviors from birth to adulthood in C57BL6/J mice.

Authors:  Vincent P Markowski; Elizabeth A Reeve; Kristen Onos; Mina Assadollahzadeh; Naomi McKay
Journal:  Neurotoxicol Teratol       Date:  2012-01-15       Impact factor: 3.763

4.  Dietary B vitamin intakes and urinary total arsenic concentration in the Health Effects of Arsenic Longitudinal Study (HEALS) cohort, Bangladesh.

Authors:  Maria Argos; Paul J Rathouz; Brandon L Pierce; Tara Kalra; Faruque Parvez; Vesna Slavkovich; Alauddin Ahmed; Yu Chen; Habibul Ahsan
Journal:  Eur J Nutr       Date:  2010-04-13       Impact factor: 5.614

5.  Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid.

Authors:  Matthew Medeiros; Xinghui Zheng; Petr Novak; Shawn M Wnek; Vivian Chyan; Claudia Escudero-Lourdes; A Jay Gandolfi
Journal:  Toxicology       Date:  2011-11-17       Impact factor: 4.221

6.  Metabolism of Inorganic Arsenic in Mice Lacking Genes Encoding GST-P, GST-M, and GST-T.

Authors:  Christelle Douillet; Beverly H Koller; Miroslav Stýblo
Journal:  Chem Res Toxicol       Date:  2020-07-29       Impact factor: 3.739

7.  Arsenic Exposure in Relation to Ischemic Stroke: The Reasons for Geographic and Racial Differences in Stroke Study.

Authors:  Cari L Tsinovoi; Pengcheng Xun; Leslie A McClure; Vivian M O Carioni; John D Brockman; Jianwen Cai; Eliseo Guallar; Mary Cushman; Frederick W Unverzagt; Virginia J Howard; Ka He
Journal:  Stroke       Date:  2017-12-06       Impact factor: 7.914

8.  Long-term health consequences of prenatal arsenic exposure: links to the genome and the epigenome.

Authors:  Kathryn Bailey; Rebecca C Fry
Journal:  Rev Environ Health       Date:  2014       Impact factor: 3.458

9.  Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer.

Authors:  Kathryn A Bailey; Kathleen Wallace; Lisa Smeester; Sheau-Fung Thai; Douglas C Wolf; Stephen W Edwards; Rebecca C Fry
Journal:  J Can Res Updates       Date:  2012-08-21

10.  Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions.

Authors:  Olga L Valenzuela; Zuzana Drobná; Erika Hernández-Castellanos; Luz C Sánchez-Peña; Gonzalo G García-Vargas; Víctor H Borja-Aburto; Miroslav Stýblo; Luz M Del Razo
Journal:  Toxicol Appl Pharmacol       Date:  2009-06-16       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.